HS
SRPT icon

Haafor (Singapore)’s Sarepta Therapeutics SRPT Stock Holding History

Haafor (Singapore)’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-2,117
Closed -$298K – 223
2020
Q3 		$298K Buy
+2,117
New +$322K 0.62% 60

Other funds holding SRPT

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Haafor (Singapore)'s SRPT Position: Q4 2020 in Review

Haafor (Singapore) sold out of Sarepta Therapeutics (SRPT) in Q4 2020, closing a stake of 2,117 shares — an estimated $298K sold.

Haafor (Singapore) first reported a position in SRPT in Q3 2020 and held it in 1 quarter. The position peaked at $298K in Q3 2020. 455 funds tracked by Wall St. Rank hold SRPT as of Q4 2020.

  • Haafor (Singapore) reported no remaining Sarepta Therapeutics position as of Q4 2020 after selling out during the quarter.
  • Haafor (Singapore) sold 2,117 Sarepta Therapeutics shares in Q4 2020, an estimated $298K.
  • Haafor (Singapore) first reported a position in Sarepta Therapeutics in Q3 2020 and held it in 1 quarter.
  • Haafor (Singapore)'s Sarepta Therapeutics position peaked at $298K in Q3 2020.
  • 455 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q4 2020.

Based on Haafor (Singapore)'s 13F filing for Q4 2020, filed 5 Feb 2021.